Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel
OTCMKTS:NVZMF

Novozymes A/S 4/23/2015 Earnings Results & Report

Novozymes A/S logo
$68.70 0.00 (0.00%)
As of 10/30/2026

Novozymes A/S beat analyst earnings expectations in results released April 23, 2015. The company reported EPS of $2.27 versus the $2.23 consensus estimate.

Research:Profile

Earnings Announcement Details

Report Date
Time
Before Market Opens

Novozymes A/S EPS Results

Actual EPS
$2.27
Consensus EPS
$2.23
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Novozymes A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Novozymes A/S Earnings FAQ

Novozymes A/S (OTCMKTS:NVZMF) reported earnings of $2.27 per share for the quarter, beating the consensus estimate of $2.23. The report was announced on Thursday, April 23, 2015.

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novozymes A/S on the company's earnings history page.

Novozymes A/S Earnings Headlines

Novonesis (Novozymes) B Class B NVZMF
July 3, 2026  |  morningstar.comM
Novonesis (Novozymes A/S): Interim report Q1 2026
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68393410-novonesis-novozymes-a-s-interim-report-q1-2026-399.htm
x
On October 3, President Trump invoked 1929, warning of a looming downturn. He repeated the comparison a week later in Tennessee. The IMF calls markets increasingly exposed to a sharp correction. Ray Dalio sees a classic bubble. Peter Schiff says a downturn is coming regardless of the election outcome. For retirees living off savings, that warning carries real weight ahead of November 3.tc pixel
November 3 at 1:00 AM  |  USA Capital Gold (Ad)
Novonesis (Novozymes A/S): Novonesis expands global footprint with acquisition of production facility in Southeast Asia
April 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68143353-novonesis-novozymes-a-s-novonesis-expands-global-footprint-with-acquisition-of-production-facility-in-southeast-asia-399.htm
Novozymes (CPSE:NSIS B): Assessing Valuation After Upward Sales Growth Guidance and Improved Q3 Results
November 12, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/novozymes-cpse-nsis-b-assessing-181100745.html
Could Gut Microbiome Research Shift Novozymes' Innovation Narrative in Health and Nutrition (CPSE:NSIS B)?
September 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/could-gut-microbiome-research-shift-135041138.html
See More Novozymes A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email.

About Novozymes A/S

Novozymes A/S (OTCMKTS:NVZMF) was a Denmark-based biotechnology company specializing in enzymes and microorganisms for industrial, agricultural, and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use, and develop more sustainable products and processes.

The company developed and marketed enzyme and microbial solutions for industries including food and beverages, household care, agriculture, bioenergy, animal health, and industrial manufacturing. Its products supported applications such as baking, brewing, detergents, textile processing, crop production, animal feed, and the conversion of biomass into renewable fuels and other materials.

Novozymes served customers across global markets through research, production, and commercial operations in multiple regions. The company was established in 2000 through the separation of the enzyme business from Novo Nordisk. In 2024, Novozymes combined with Chr. Hansen Holding A/S to form Novonesis, and Novozymes ceased operating as a standalone company under its former name.

View Novozymes A/S Profile
Earnings Tools